Needham & Company Maintains a 'Buy' on Biolase Technology (BLTI); Updating Estimates for 3Q10 Actual Results and Other Recent Developments
Tweet Send to a Friend
Needham & Company maintains a 'Buy' on Biolase Technology (NASDAQ: BLTI), lowers PT from $4 to $3.
Needham analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Needham analyst says ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
